Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
News
Recent Posts
- Netherlands approves trial of brain implant for ALS communication
- MLB, advocacy groups step up to the plate for ALS on annual Lou Gehrig Day
- ‘Emily in Paris’ actor Pierre Deny dies following severe case of ALS
- Why I continue to volunteer and stay involved in ALS causes
- We replace an old feeding tube part with a ‘lifetime supply’ of new parts